You have read all your free articles, to continue reading subscribe to read the rest of this content.
Targovax’s ONCOS-102 mesothelioma 12-month data demonstrate broad immune activation linked to clinical benefit and the company announces a new collaboration with Merck. Targovax has released 12-month efficacy and immunological data from the randomized phase I/II trial of ONCOS-102 in combinatioAlready a subscriber Login You have read all your free articles,…
PILA PHARMA has announced that its phase 2a trial, PP-CT02, designed to investigate the efficacy and safety following 28 days dosing of XEN-D0501 4 milligrams twice daily as compared to placebo in patients with type 2 diabetes, has been successfully completed. No serious adverse events were obserAlready a subscriber Login…
Vakona has signed an agreement with French company GTP Tech to initiate the first manufacturing steps of its acne medicine. GTP Tech, a GTP Bioways company, will develop the industrial process to move on from the preclinical phase towards the manufacturing of antibiotic-free treatment for clinicsAlready a subscriber Login You…
Immedica Pharma has announced that RAVICTI has been accepted and granted Priority Review for the New Drug Application (NDA) in China. In April, another submission for RAVICTI Market Authorisation Approval was accepted by the Department of Health (DoH) in HongKong. “With these submissions inAlready a subscriber Login You have read all…
